Interventional Oncology Devices – Market Insights – Europe

The European interventional oncology device market is projected to see modest growth through 2034, driven by rising cancer incidence and prevalence rates, updated clinical guidelines, and emerging clinical data supporting ablation and embolization procedures as standard-of-care treatments. Increasing preference for minimally invasive procedures over surgery, improved reimbursement, and physician acceptance will drive adoption. However, growth will be hindered by mixed clinical data, pricing pressures, and regional cost constraints.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in Europe from 2019 to 2034.

The ablation device market is dominated by microwave ablation; however, new technologies are increasingly being adopted.

What factors are driving growth within the microwave ablation device segment?

How will the increasing adoption of cryoablation change the market dynamics in the microwave and RF ablation device segments?

Will changing reimbursement guidelines increase the adoption of IRE devices? What has driven or limited their growth in the market?

What are the strategies employed by key competitors to position themselves in the ablation device market, and what challenges do they face? Which competitors are leaving certain market segments?

Which major clinical trials are being conducted, and how will they impact the interventional oncology device market?

Ablation therapy procedures will continue to grow for the liver, kidney, and lung cancer indications.

How does resection compete against the ablation techniques? What new studies and guidelines will increase the adoption of ablation therapies over resection?

How is RF competing against microwave ablation devices?

What are the advantages and disadvantages of each type of ablation device offered by competitors, and how do these differences affect adoption for different indications?

How will growth vary across different ablation device categories?

DEBs and radioembolization spheres are seeing increasing adoption.

What is the adoption outlook for different embolization devices, and what factors will affect the penetration of these technologies over the forecast period?

How will the rise in clinical trials influence the adoption of radioembolization spheres in cancer treatment?

How will the market growth vary across different embolization device categories?

How are radioembolization spheres being adopted by physicians in the European market? Why have holmium-166 radioembolization spheres been discontinued from the market?